Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.7 USD | +0.57% | -2.96% | -32.21% |
Apr. 26 | CVS Omnicare staff in Las Vegas vote to join new union | RE |
Apr. 26 | Morgan Stanley Adjusts Price Target on Walgreens Boots Alliance to $16 From $20 | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.15 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.21% | 15.18B | B- | ||
-31.97% | 10.1B | B | ||
+8.14% | 6.12B | C | ||
-11.41% | 5.97B | C+ | ||
-30.42% | 5.65B | B | ||
-0.88% | 4.71B | D- | ||
+51.58% | 4.26B | - | C | |
-12.31% | 3.58B | B | ||
-14.86% | 3.26B | C- | ||
-6.93% | 3.07B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- WBA Stock
- Ratings Walgreens Boots Alliance, Inc.